TB-500 (10 mg Vial) Dosage Protocol

Dosing & Reconstitution Overview

TB-500 is a synthetic peptide built around the N-terminal active region of thymosin beta-4, the actin-binding heptapeptide sequence Ac-LKKTETQ. The figures below are compiled strictly for laboratory and educational reference — they describe how the compound has been handled and measured in published work, not a recommendation for use in humans or animals.

For a 10 mg vial, adding 3.0 mL of bacteriostatic water yields a concentration of roughly 3.33 mg/mL (≈3,333 mcg/mL). At that fill, each unit drawn on a U-100 insulin syringe equals 0.01 mL and delivers about 33.3 mcg, so a 500 mcg measurement works out to roughly 15 units. This dilution keeps daily microgram amounts inside an easy-to-read region of the syringe barrel.

Standard (Gradual) Titration Schedule

The gradual schedule steps a daily microgram amount upward across an 8–12 week reference window, holding each level for one to several weeks before increasing it so tolerability can be observed at the lower amounts first.

Reconstitution Steps

1. Let the sealed lyophilized vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab.
2. Draw 3.0 mL of bacteriostatic water and inject it slowly down the inside wall of the vial — never directly onto the powder pellet, which helps avoid foaming.
3. Roll and swirl the vial gently until the powder is fully dissolved. Do not shake; aggressive agitation can shear the peptide.
4. The solution should be clear and colourless. Label the vial with the concentration (~3.33 mg/mL) and the reconstitution date.
5. Store upright under refrigeration between uses and draw subsequent volumes with a fresh sterile syringe each time.

Advanced (Loading-Phase) Schedule

Some handling references front-load the schedule with a higher weekly total during an initial window, then drop to a lower maintenance amount. This pattern reaches a larger cumulative early exposure before settling into a steady once- or twice-weekly cadence.

Supplies Needed

• TB-500 vials (10 mg): ~4 vials for an 8-week run; ~7 vials for a 12-week run; ~10 vials for a 16-week run.
• Insulin syringes (U-100, 1 mL): ~56 for 8 weeks, ~84 for 12 weeks, ~112 for 16 weeks (one fresh syringe per draw).
• Bacteriostatic water (10 mL): two bottles for 8 weeks; three bottles for a 12–16 week run.
• Alcohol swabs: two 100-count boxes cover an 8–12 week schedule; three boxes for 16 weeks.

Protocol Overview

• Research goal: model actin-binding, cell-migration and angiogenesis activity associated with the thymosin β4 active fragment.
• Schedule: once-daily subcutaneous administration in the gradual model; weekly cadence in loading/maintenance variants.
• Dose band: 500–1000 mcg per dose, ~5 mg/week average.
• Fill: 10 mg lyophilized, reconstituted to ~3.33 mg/mL with 3 mL diluent.
• Storage: −20 °C dry; 2–8 °C once reconstituted.

Dosing Protocol Notes

• Begin at the lowest 500 mcg step and hold it for one to two weeks before escalating.
• Keep administration on a fixed daily time where possible for steady exposure modelling.
• Rotate the measurement/administration site each day to limit local irritation.
• Escalate only after tolerability is established at the prior step.

Storage Instructions

Keep sealed lyophilized vials at −20 °C (−4 °F), in dry, dark conditions, where stability extends for many months. Once reconstituted with bacteriostatic water, refrigerate at 2–8 °C (35.6–46.4 °F) and use within about 28 days; do not freeze the reconstituted solution. Allow refrigerated solution to warm slightly before drawing and avoid repeated freeze-thaw cycles.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Rotate sampling technique to keep the stopper intact across many draws.
• Protect the vial from light during refrigerated storage.
• Document each draw — date, volume, remaining material — for reproducibility.

How TB-500 Works

TB-500 corresponds to the active heptapeptide region (Ac-LKKTETQ) of thymosin beta-4, a naturally occurring actin-sequestering protein. The fragment is studied for its ability to bind actin and promote cell migration, new blood-vessel formation (angiogenesis) and tissue repair. By influencing actin dynamics it is reported to support cell motility and the cellular movement involved in wound closure, and it is associated indirectly with reduced inflammation and fibrosis in model systems. Its mechanism is distinct from growth-factor or receptor-agonist peptides, acting instead on the cytoskeletal machinery of cell movement.

Reported Benefits & Side Effects

Effects reported in research

• Accelerated wound healing and tissue repair in preclinical models.
• Enhanced angiogenesis and cell migration linked to actin-binding activity.
• Indirect reductions in local inflammation and fibrosis in some model systems.

Side effects reported

• Generally well tolerated in the limited available data.
• Occasional mild injection-site reactions such as redness or tenderness.
• Human safety data are limited; no large-scale clinical trials have been completed.

Injection/Handling Technique (Reference Only)

• Wipe the vial stopper and the site with alcohol swabs and let them air dry.
• Pinch a skinfold and insert subcutaneously at a 45–90° angle depending on needle length; aspiration is not required for subcutaneous work.
• Inject slowly and wait roughly 5–10 seconds before withdrawing the needle.
• Rotate sites systematically (abdomen, thighs, upper arms) and dispose of sharps in an approved container.

References

Related Protocols